AAAAAA

   
Results: 1-10 |
Results: 10
DOCETAXEL (TAXOTERE) - AN ACTIVE AGENT IN METASTATIC UROTHELIAL CANCER - RESULTS OF A PHASE-II STUDY IN NON-CHEMOTHERAPY-PRETREATED PATIENTS
Authors: DEWIT R KRUIT WHJ STOTER G DEBOER M KERGER J VERWEIJ J
Citation: R. Dewit et al., DOCETAXEL (TAXOTERE) - AN ACTIVE AGENT IN METASTATIC UROTHELIAL CANCER - RESULTS OF A PHASE-II STUDY IN NON-CHEMOTHERAPY-PRETREATED PATIENTS, British Journal of Cancer, 78(10), 1998, pp. 1342-1345
A PHASE-I PHASE-II STUDY OF MULTICYCLIC DOSE-INTENSIVE CHEMOTHERAPY SUPPORTED WITH G-CSF, OR G-CSF AND HEMATOPOIETIC PROGENITOR CELLS IN WHOLE-BLOOD, IN 2 CONSECUTIVE COHORTS OF PATIENTS/
Authors: DEWIT R KRUIT WHJ LAMERS CHJ VANTVEER MB LUYTEN AA VANBEURDEN V HARTEVELD M PLANTING AST SCHMITZ PIM STOTER G BOLHUIS RLH VERWEIJ J
Citation: R. Dewit et al., A PHASE-I PHASE-II STUDY OF MULTICYCLIC DOSE-INTENSIVE CHEMOTHERAPY SUPPORTED WITH G-CSF, OR G-CSF AND HEMATOPOIETIC PROGENITOR CELLS IN WHOLE-BLOOD, IN 2 CONSECUTIVE COHORTS OF PATIENTS/, British Journal of Cancer, 77(12), 1998, pp. 2363-2366
HIGH-DOSE REGIMEN OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN COMBINATION WITH LYMPHOKINE-ACTIVATED KILLER-CELLS IN PATIENTS WITH METASTATIC RENAL-CELL-CANCER
Authors: KRUIT WHJ GOEY SH LAMERS CHJ GRATAMA JW VISSER B SCHMITZ PIM EGGERMONT AMM BOLHUIS RLH STOTER G
Citation: Whj. Kruit et al., HIGH-DOSE REGIMEN OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN COMBINATION WITH LYMPHOKINE-ACTIVATED KILLER-CELLS IN PATIENTS WITH METASTATIC RENAL-CELL-CANCER, Journal of immunotherapy with emphasis on tumor immunology, 20(4), 1997, pp. 312-320
WEEKLY HIGH-DOSE CISPLATIN (P) AND DAILY ORAL VEPESID (VP) - A HIGHLY-ACTIVE SALVAGE REGIMEN FOR PROGRESSIVE OR RECURRENT OVARIAN-CANCER AFTER PLATINUM THERAPY
Authors: VANDERBURG MEL LOGMANS A DEWIT R VANLENT M KRUIT WHJ STOTER G VERWEIJ J
Citation: Mel. Vanderburg et al., WEEKLY HIGH-DOSE CISPLATIN (P) AND DAILY ORAL VEPESID (VP) - A HIGHLY-ACTIVE SALVAGE REGIMEN FOR PROGRESSIVE OR RECURRENT OVARIAN-CANCER AFTER PLATINUM THERAPY, European journal of cancer, 33, 1997, pp. 529-529
THE ROLE OF ADOPTIVE IMMUNOTHERAPY IN SOLID CANCERS
Authors: KRUIT WHJ STOTER G
Citation: Whj. Kruit et G. Stoter, THE ROLE OF ADOPTIVE IMMUNOTHERAPY IN SOLID CANCERS, Netherlands journal of medicine, 50(2), 1997, pp. 47-68
ADVERSE EFFECT ON BONE-MARROW PROTECTION OF PRECHEMOTHERAPY GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT
Authors: DEWIT R VERWEIJ J BONTENBAL M KRUIT WHJ SEYNAEVE C SCHMITZ PIM STOTER G
Citation: R. Dewit et al., ADVERSE EFFECT ON BONE-MARROW PROTECTION OF PRECHEMOTHERAPY GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT, Journal of the National Cancer Institute, 88(19), 1996, pp. 1393-1398
DOSE EFFICACY STUDY OF 2 SCHEDULES OF HIGH-DOSE BOLUS ADMINISTRATION OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN METASTATIC MELANOMA
Authors: KRUIT WHJ PUNT CJA GOEY SH DEMULDER PHM GRATAMA JW EGGERMONT AMM BOLHUIS RLH STOTER G
Citation: Whj. Kruit et al., DOSE EFFICACY STUDY OF 2 SCHEDULES OF HIGH-DOSE BOLUS ADMINISTRATION OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN METASTATIC MELANOMA, British Journal of Cancer, 74(6), 1996, pp. 951-955
2ND-LINE CHEMOTHERAPY WITH LONG-TERM LOW-DOSE ORAL ETOPOSIDE IN PATIENTS WITH ADVANCED BREAST-CANCER
Authors: BONTENBAL M PLANTING AST VERWEIJ J DEWIT R KRUIT WHJ STOTER G KLIJN JGM
Citation: M. Bontenbal et al., 2ND-LINE CHEMOTHERAPY WITH LONG-TERM LOW-DOSE ORAL ETOPOSIDE IN PATIENTS WITH ADVANCED BREAST-CANCER, Breast cancer research and treatment, 34(2), 1995, pp. 185-189
FINAL REPORT OF A PHASE-II STUDY OF INTERLEUKIN-2 AND INTERFERON ALPHA IN PATIENTS WITH METASTATIC MELANOMA
Authors: KRUIT WHJ GOEY SH CALABRESI F LINDEMANN A STAHEL RA POLIWODA H OSTERWALDER B STOTER G
Citation: Whj. Kruit et al., FINAL REPORT OF A PHASE-II STUDY OF INTERLEUKIN-2 AND INTERFERON ALPHA IN PATIENTS WITH METASTATIC MELANOMA, British Journal of Cancer, 71(6), 1995, pp. 1319-1321
INTERLEUKIN-2-INDUCED THYROID-DYSFUNCTION IS CORRELATED WITH TREATMENT DURATION BUT NOT WITH TUMOR RESPONSE
Authors: KRUIT WHJ BOLHUIS RLH GOEY SH JANSEN RLH EGGERMONT AMM BATCHELOR D SCHMITZ PIM STOTER G
Citation: Whj. Kruit et al., INTERLEUKIN-2-INDUCED THYROID-DYSFUNCTION IS CORRELATED WITH TREATMENT DURATION BUT NOT WITH TUMOR RESPONSE, Journal of clinical oncology, 11(5), 1993, pp. 921-924
Risultati: 1-10 |